Chest cancer study seeks clues in blood and tissue to improve future treatments
NCT ID NCT01385722
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This research study collects blood, tumor tissue, and other body fluids from 1,000 adults with lung cancer, thymus cancer, or mesothelioma. The goal is to analyze these samples to find biological markers that could predict how the disease will progress or which treatments might work best. Participants provide samples and complete a questionnaire, but no experimental treatment is given.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA OF UNKNOWN PRIMARY CONSISTENT WITH PRIMARY THORACIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University School of Medicine
Stanford, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success
- Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
- Can a new PET tracer light up hidden cancers?